University College Hospital Galway
Galway, Ireland
NCT Number: NCT03379922
Extracorporeal shockwave lithotripsy is an outpatient treatment for patients with intrarenal calculi. Standard of care involves offering oral analgesia prior to commencing the treatment. Most patients do not take the offered analgesia after the initial treatment. It has been suggested that distraction techniques may be equivalent to oral analgesia in improving tolerability of extracorporeal shockwave lithotripsy treatment. The use of distraction techniques also removes the potential side effects of mediation administration.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Galway, Ireland
The investigators are aiming to assess if distraction techniques help improve patient comfort while undergoing extracorporeal shockwave lithotripsy treatment for renal calculi. Improved tolerability of treatment would result in longer duration of time on the lithotripsy machine and may lead to better stone fragmentation. Outcomes will be completion of treatment and scores on the short form McGill pain questionnaire.
Patients will be randomised into three groups. The randomisation will not be blinded as this is not possible within the design of the study. The first group will be given stress balls to squeeze during treatment and will also receive standard care (the offer of oral analgesia). The second group will be given headphones to listen to music during treatment and will also receive standard care. The third group will receive standard care.
Prior to commencing extracorporeal shockwave lithotripsy, patients will be given the shortened Health Anxiety Inventory score to complete. Following lithotripsy treatment, patients will be given the short form McGill pain questionnaire to complete.
The initial pilot study will aim to recruit sixty patients and further recruitment will take place on the basis of the outcomes of the pilot study.
Inclusion criteria
All patients over eighteen years old undergoing extracorporeal shockwave lithotripsy for the first time
Exclusion criteria
Patients not capable of giving informed consent Patients in whom extracorporeal shockwave lithotripsy is contraindicated
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Squeezing stress balls while receiving ESWL treatment
Listening to music while receiving ESWL treatment
Time frame: At the time of completing lithotripsy treatment (3000 shocks over 40 to 60 minutes)
Patients will complete the short form McGill pain questionnaire, subdivided into 11 sensory descriptors, 4 affective descriptors and a visual analogue score. Sensory and affective descriptors are each rated as 0-3. Sensory minimum score 0/33 (no pain), maximum score 33/33 (maximum pain). Affective minimum score 0/12 (no pain), maximum score 12/12 (maximum pain). Visual analogue score 0 to 10 (0 being no pain and 10 being worst possible pain).
Time frame: At the time of completing lithotripsy treatment (3000 shocks over 40 to 60 minutes)
Cessation of lithotripsy treatment before completion (3000 shocks over 40-60 minutes)
Cliodhna Browne
Other
A Randomised Control Trial of Strategies to Maximise Patient Comfort During Extracorporeal Shockwave Lithotripsy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07457983
Calculi, Female Urogenital Diseases
Adıyaman, Turkey (Türkiye)
View Trial DetailsNCT07715643
Calcium Oxalate Kidney Stones, Female Urogenital Diseases
Lahore, Pakistan
View Trial DetailsNCT02214836
Calculi, Female Urogenital Diseases
Seattle, Washington, United States
View Trial DetailsNCT07377461
Calculi, Female Urogenital Diseases
Ashkelon, Israel
View Trial Details